Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

High density lipoprotein: guardian of the vascular system?

Packard C, Nunn A, Hobbs R; Future Forum Editorial Board.

Int J Clin Pract. 2002 Dec;56(10):761-71. Review.

PMID:
12510950
2.

Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C.

Chapman MJ, Assmann G, Fruchart JC, Shepherd J, Sirtori C; European Consensus Panel on HDL-C.

Curr Med Res Opin. 2004 Aug;20(8):1253-68. Review.

PMID:
15324528
3.

Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.

Hausenloy DJ, Yellon DM.

Heart. 2008 Jun;94(6):706-14. doi: 10.1136/hrt.2007.125401. Review.

PMID:
18480348
4.
5.

HDL-C: role as a risk modifier.

Barter P.

Atheroscler Suppl. 2011 Nov;12(3):267-70. doi: 10.1016/S1567-5688(11)70885-6. Review.

PMID:
22152280
6.

Role of fibric acid derivatives in the management of risk factors for coronary heart disease.

Després JP, Lemieux I, Robins SJ.

Drugs. 2004;64(19):2177-98. Review.

PMID:
15456334
7.

Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.

Evans M, Roberts A, Davies S, Rees A.

Drugs. 2004;64(11):1181-96. Review.

PMID:
15161326
8.

Defining specific goals of therapy in treating dyslipidemia in the patient with low high-density lipoprotein cholesterol.

Belalcazar LM, Ballantyne CM.

Prog Cardiovasc Dis. 1998 Sep-Oct;41(2):151-74. Review.

PMID:
9790415
9.

Lipoprotein abnormalities and their consequences for patients with type 2 diabetes.

Krentz AJ.

Diabetes Obes Metab. 2003 Nov;5 Suppl 1:S19-27. Review.

PMID:
14984018
10.
11.

The lipid triad in type 2 diabetes - prevalence and relevance of hypertriglyceridaemia/low high-density lipoprotein syndrome in type 2 diabetes.

Temelkova-Kurktschiev T, Hanefeld M.

Exp Clin Endocrinol Diabetes. 2004 Feb;112(2):75-9. Review.

PMID:
15031770
12.
13.

Optimal therapy of low levels of high density lipoprotein-cholesterol.

Kashyap ML, Tavintharan S, Kamanna VS.

Am J Cardiovasc Drugs. 2003;3(1):53-65. Review.

PMID:
14727946
14.

HDL-c is a powerful lipid predictor of cardiovascular diseases.

Bruckert E, Hansel B.

Int J Clin Pract. 2007 Nov;61(11):1905-13. Epub 2007 Jul 26. Review.

PMID:
17655681
15.

Emerging importance of HDL cholesterol in developing high-risk coronary plaques in acute coronary syndromes.

Viles-Gonzalez JF, Fuster V, Corti R, Badimon JJ.

Curr Opin Cardiol. 2003 Jul;18(4):286-94. Review.

PMID:
12858127
16.

Pharmacologic management of isolated low high-density lipoprotein syndrome.

Bermúdez V, Cano R, Cano C, Bermúdez F, Arraiz N, Acosta L, Finol F, Pabón MR, Amell A, Reyna N, Hidalgo J, Kendall P, Manuel V, Hernández R.

Am J Ther. 2008 Jul-Aug;15(4):377-88. doi: 10.1097/MJT.0b013e318169bc0b. Review.

PMID:
18645343
17.

Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease.

Chapman MJ.

Pharmacol Ther. 2006 Sep;111(3):893-908. Epub 2006 Mar 29. Review.

PMID:
16574234
18.

Management of dyslipidemia in the metabolic syndrome: recommendations of the Spanish HDL-Forum.

Ascaso J, Gonzalez Santos P, Hernandez Mijares A, Mangas Rojas A, Masana L, Millan J, Pallardo LF, Pedro-Botet J, Perez Jimenez F, Pintó X, Plaza I, Rubiés J, Zúñiga M.

Am J Cardiovasc Drugs. 2007;7(1):39-58. Review. Erratum in: Am J Cardiovasc Drugs. 2007;7(4):302.

PMID:
17355165
20.

Low HDL-C: a secondary target of dyslipidemia therapy.

Rosenson RS.

Am J Med. 2005 Oct;118(10):1067-77. Review.

PMID:
16194634

Supplemental Content

Support Center